A vascular bioregulator peptide that supports endothelial integrity and vessel wall health.
A tripeptide (Lys-Glu-Asp) bioregulator targeting vascular endothelial tissue. Research suggests it normalises endothelial gene expression, reduces markers of endothelial dysfunction, and may improve microcirculation by supporting vessel wall structure and reducing inflammatory gene activation.
Vesugen is used in Russian cardiovascular medicine as a vascular bioregulator, particularly in elderly patients with endothelial dysfunction and atherosclerotic risk. It is often combined with Cardiogen for comprehensive cardiovascular bioregulation.
Endothelial dysfunction is considered a precursor to and driver of most cardiovascular disease. Bioregulators targeting endothelial gene expression represent a preventive approach in the Khavinson framework.